JP2023545579A5 - - Google Patents
Info
- Publication number
- JP2023545579A5 JP2023545579A5 JP2023546368A JP2023546368A JP2023545579A5 JP 2023545579 A5 JP2023545579 A5 JP 2023545579A5 JP 2023546368 A JP2023546368 A JP 2023546368A JP 2023546368 A JP2023546368 A JP 2023546368A JP 2023545579 A5 JP2023545579 A5 JP 2023545579A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- seq
- antibody
- cdr3
- cdr2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2020903624 | 2020-10-07 | ||
| AU2020903624A AU2020903624A0 (en) | 2020-10-07 | Methods and agents for the treatment of ocular disease | |
| PCT/AU2021/051173 WO2022073072A1 (en) | 2020-10-07 | 2021-10-07 | Methods and agents for the treatment of ocular disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023545579A JP2023545579A (ja) | 2023-10-30 |
| JP2023545579A5 true JP2023545579A5 (https=) | 2024-10-11 |
Family
ID=81127099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023546368A Pending JP2023545579A (ja) | 2020-10-07 | 2021-10-07 | 眼疾患の治療のための方法と薬剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US11618782B2 (https=) |
| EP (1) | EP4225796A4 (https=) |
| JP (1) | JP2023545579A (https=) |
| KR (1) | KR20230086713A (https=) |
| CN (1) | CN116710135A (https=) |
| AU (1) | AU2021356298A1 (https=) |
| IL (1) | IL301762A (https=) |
| WO (1) | WO2022073072A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3886946A1 (en) | 2019-06-05 | 2021-10-06 | Regeneron Pharmaceuticals, Inc. | Devices and methods for precision dose delivery |
| AU2021356298A1 (en) | 2020-10-07 | 2023-05-04 | Line 6 Biotechnology, Inc | Methods and agents for the treatment of ocular disease |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5820858A (en) | 1993-05-28 | 1998-10-13 | The Scripps Research Institute | Methods and compositions for inhibiting CD14 mediated cell activation |
| AU2001290315A1 (en) | 2000-11-22 | 2002-06-03 | Mochida Pharmaceutical Co., Ltd. | Anti-cd14 monoclonal antibody having effect of inhibiting cd14/tlr binding |
| WO2006063292A1 (en) * | 2004-12-08 | 2006-06-15 | Icos Corporation | Recombinant method for making multimeric proteins |
| US20060257411A1 (en) * | 2005-05-06 | 2006-11-16 | Bruce Beutler | Compositions and methods for modulating cells via CD14 and toll-like receptor 4 signaling pathway |
| WO2009002790A2 (en) * | 2007-06-26 | 2008-12-31 | Bausch & Lomb Incorporated | Compositions and methods for treating, reducing, ameliorating, alleviating, or preventing dry eye |
| WO2009089401A2 (en) * | 2008-01-10 | 2009-07-16 | Bausch & Lomb Incorporated | Compositions comprising toll-like receptor or coreceptor antagonists and methods for treating or controlling ocular allergy using same |
| PT3065761T (pt) * | 2013-11-05 | 2020-02-21 | Allergan Inc | Método de tratamento de condições oculares com um darpin anti-vegf |
| AU2014370404A1 (en) * | 2013-12-24 | 2016-07-07 | Novelmed Therapeutics, Inc. | Compositions and methods of treating ocular diseases |
| EP2898896A1 (en) * | 2014-01-22 | 2015-07-29 | Université Pierre et Marie Curie (Paris 6) | Agents for use in the treatment of retinal inflammation |
| US20160038589A1 (en) * | 2014-08-11 | 2016-02-11 | Ophthotech Corporation | Methods for treating or preventing ophthalmological conditions |
| US10407510B2 (en) * | 2015-10-30 | 2019-09-10 | Genentech, Inc. | Anti-factor D antibodies and conjugates |
| IL309046B2 (en) * | 2017-04-21 | 2025-03-01 | Implicit Bioscience Ltd | CD14 antagonist antibodies for the treatment of neurodegenerative diseases |
| KR20190059164A (ko) * | 2017-11-22 | 2019-05-30 | 건국대학교 글로컬산학협력단 | 가용성 cd14의 당뇨황반부종 진단 및 치료 용도 |
| AU2021356298A1 (en) | 2020-10-07 | 2023-05-04 | Line 6 Biotechnology, Inc | Methods and agents for the treatment of ocular disease |
-
2021
- 2021-10-07 AU AU2021356298A patent/AU2021356298A1/en active Pending
- 2021-10-07 EP EP21876765.5A patent/EP4225796A4/en active Pending
- 2021-10-07 CN CN202180082106.9A patent/CN116710135A/zh active Pending
- 2021-10-07 WO PCT/AU2021/051173 patent/WO2022073072A1/en not_active Ceased
- 2021-10-07 JP JP2023546368A patent/JP2023545579A/ja active Pending
- 2021-10-07 IL IL301762A patent/IL301762A/en unknown
- 2021-10-07 KR KR1020237015441A patent/KR20230086713A/ko active Pending
-
2022
- 2022-02-23 US US17/678,861 patent/US11618782B2/en active Active
-
2023
- 2023-01-27 US US18/160,355 patent/US12258390B2/en active Active
-
2025
- 2025-02-21 US US19/060,422 patent/US20250230228A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7646727B2 (ja) | 眼科疾患の処置 | |
| JP2023545579A5 (https=) | ||
| JP7695187B2 (ja) | ＨＰＴＰ－β（ＶＥ－ＰＴＰ）およびＶＥＧＦを標的にする多特異性抗体 | |
| TWI785360B (zh) | 眼科疾病之個人化治療 | |
| ES2384110T3 (es) | Anticuerpo anti-PLGF novedoso | |
| JP2016504416A5 (https=) | ||
| JP5990511B2 (ja) | 血管新生に基づく眼障害の処置のための抗ｃｄ１６０特異的抗体 | |
| CN104995303A (zh) | 利用结合乙酰透明质酸的肽标签的组合物和方法 | |
| JP2010528047A5 (https=) | ||
| MX2014004449A (es) | Tratamiento de enfermedad ocular. | |
| EA039807B1 (ru) | Антитело к -синуклеину и его применение | |
| CA3049110A1 (en) | Anti-.alpha.-syn antibody and use thereof | |
| JP2017502023A (ja) | 眼疾患を治療する組成物および方法 | |
| CN113166244B (zh) | 稳定性得到提高的抗c-肝细胞生长因子受体抗体或其抗原结合片段 | |
| EP2563395A2 (en) | Anti-s1p antibody treatment of patients with ocular disease | |
| JP2024508736A (ja) | 補体ｃ３抗原結合タンパク質 | |
| JP2011503094A5 (https=) | ||
| JP2022547537A (ja) | 眼疾患を治療するための方法 | |
| JP2020518641A5 (https=) |